Equities

IXICO PLC

IXI:LSE

IXICO PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)7.00
  • Today's Change0.00 / 0.00%
  • Shares traded311.35k
  • 1 Year change-63.16%
  • Beta0.6614
Data delayed at least 20 minutes, as of Jul 05 2024 16:04 BST.
More ▼

Profile data is unavailable for this security.

About the company

IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.

  • Revenue in GBP (TTM)6.00m
  • Net income in GBP-1.87m
  • Incorporated1995
  • Employees89.00
  • Location
    IXICO PLC4th Fl, Griffin Court, 15 Long LaneLONDON EC1A 9PNUnited KingdomGBR
  • Phone+44 20 3763 7499Fax+44 20 7209 2473
  • Websitehttps://ixico.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Ovoca Bio PLC0.00-4.32m712.55k5.00712.55k5.00
ReNeuron Group Plc249.00k-5.07m1.93m34.001.93m34.00
Fusion Antibodies PLC1.58m-2.84m2.91m50.002.91m50.00
IXICO PLC6.00m-1.87m3.38m89.003.38m89.00
TheraCryf PLC396.00k-3.14m3.63m9.003.63m9.00
ValiRx Plc9.60k-2.04m3.90m8.003.90m8.00
Cizzle Biotechnology Holdings PLC0.00-1.72m7.53m67.007.53m67.00
Destiny Pharma PLC0.00-5.66m8.14m19.008.14m19.00
Genflow Biosciences PLC0.00-1.63m8.39m5.008.39m5.00
ImmuPharma PLC0.00-2.92m8.95m5.008.95m5.00
Synairgen plc0.00-8.41m9.96m36.009.96m36.00
Bivictrix Therapeutics PLC0.00-2.55m10.73m12.0010.73m12.00
Data as of Jul 05 2024. Currency figures normalised to IXICO PLC's reporting currency: UK Pound GBX

Institutional shareholders

52.92%Per cent of shares held by top holders
HolderShares% Held
BGF Investment Management Ltd.as of 04 Dec 20238.92m18.46%
Octopus Investments Ltd.as of 04 Dec 20236.41m13.25%
Canaccord Genuity Wealth Ltd.as of 30 Mar 20214.68m9.69%
Hargreaves Lansdown Asset Management Ltd.as of 01 May 20242.66m5.50%
City Asset Management Plcas of 29 Jan 20241.43m2.95%
ICBC Standard Bank Plcas of 01 May 2024610.00k1.26%
Pilling & Co. Stockbrokers Ltd.as of 01 May 2024367.00k0.76%
HSBC Global Asset Management (UK) Ltd.as of 01 May 2024222.00k0.46%
Acadian Asset Management LLCas of 01 May 2024151.00k0.31%
BG Fund Management Luxembourg SAas of 01 May 2024137.00k0.28%
More ▼
Data from 31 Mar 2024 - 02 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.